The 21-0004 protocol will evaluate the safety and immunogenicity of SARS-CoV-2 administered during pregnancy or postpartum. The Seattle Children’s Research Institute, a subcontractor to the Kaiser Washington VTEU, has been selected to perform SARS-CoV-2 pseudovirus neutralization assays for the 21-0004 trial. The NIH will provide funds for the assay work to the Kaiser Washington VTEU, which will then provide funds to the Seattle Children’s Research Institute via the existing subcontract. Kaiser Washington is not a clinical site for the 21-0004 trial and the work of the subcontractor is the only involvement of Kaiser Washington in that trial.